Twist Bioscience (TWST) to Release Earnings on Thursday

Twist Bioscience (NASDAQ:TWST) is scheduled to be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect Twist Bioscience to post earnings of ($0.84) per share for the quarter. Twist Bioscience has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. The business had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business’s quarterly revenue was up 31.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.74) EPS. On average, analysts expect Twist Bioscience to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Twist Bioscience Trading Down 2.4 %

NASDAQ:TWST opened at $30.75 on Thursday. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -8.52 and a beta of 1.62. The firm’s fifty day simple moving average is $35.15 and its 200 day simple moving average is $30.32. Twist Bioscience has a twelve month low of $11.46 and a twelve month high of $43.21.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the sale, the chief executive officer now owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the sale, the chief executive officer now owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The disclosure for this sale can be found here. Insiders sold a total of 11,037 shares of company stock valued at $384,092 in the last quarter. Insiders own 3.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TWST shares. Barclays cut their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. Scotiabank upped their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their target price for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.